<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-929" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Prazosin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Basquez</surname>
            <given-names>Ryan</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pippin</surname>
            <given-names>Micah M.</given-names>
          </name>
          <aff>LSUHSC Shreveport</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ryan Basquez declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Micah Pippin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-929.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Prazosin is a medication used to manage and treat hypertension, benign prostatic hyperplasia, PTSD-associated nightmares, and the Raynaud phenomenon. It is a quinazoline derivative that acts as a competitive alpha1-antagonist. This activity describes the indications, action, and contraindications for prazosin as a valuable agent in treating and managing various conditions for which it has indications. This activity will highlight the mechanism of action, adverse event profile, and other key factors pertinent to healthcare providers.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of prazosin.</p></list-item><list-item><p>Describe the potential adverse effects of prazosin.</p></list-item><list-item><p>Review the appropriate monitoring for patients receiving therapy with prazosin.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to advance and improve outcomes using prazosin.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=929&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=929">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-929.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA Approved Indications</bold>
</p>
        <p>Prazosin is FDA approved for the treatment of hypertension alone or in combination with other antihypertensive agents. However, this medication is not a first-line agent based on current evidence-based guidelines.<xref ref-type="bibr" rid="article-929.r1">[1]</xref>&#x000a0;</p>
        <p>
<bold>Non-FDA Approved Indications/Off-label Use&#x000a0;</bold>
</p>
        <p>Prazosin has therapeutic use for benign prostatic hypertrophy (BPH), post-traumatic stress disorder (PTSD) associated nightmares, Raynaud phenomenon, pheochromocytoma, and scorpion envenomation.&#x000a0;</p>
        <p>Prazosin was the first alpha antagonist used for BPH. The medication is traditionally used multiple times per day, and as a result, longer-acting alpha antagonists have come to market, which provides convenience.<xref ref-type="bibr" rid="article-929.r2">[2]</xref></p>
        <p>Prazosin may reduce PTSD-associated nightmares. A systematic review by Kung et al. suggests that there is a benefit as compared to placebo in reducing the frequency and duration of nightmares.<xref ref-type="bibr" rid="article-929.r3">[3]</xref>&#x000a0;However, the literature review was in a population that already had PTSD. It is unclear whether or not this medication will reduce the risk of nightmares in people without PTSD.&#x000a0;&#x000a0;</p>
        <p>Prazosin has been used in primary Raynaud phenomenon with 1mg three times daily. This intervention showed benefit in some of the patients that received treatment.<xref ref-type="bibr" rid="article-929.r4">[4]</xref></p>
        <p>Pheochromocytomas cause catecholamine surges and perioperative use of an alpha antagonist can help abate the associated symptoms. Traditionally, clinicians have used phenoxybenzamine; however, comparison among phenoxybenzamine, doxazosin, and prazosin has shown varying results.<xref ref-type="bibr" rid="article-929.r5">[5]</xref>&#x000a0;Prazosin may be used as an alternative to phenoxybenzamine as it is much cheaper, and it is unclear which medication is the most efficacious.</p>
        <p>A study in India on pediatric patients, with a sample size of 36, suggests that using prazosin in combination with standard therapy lowers mortality of envenomation from a scorpion sting.<xref ref-type="bibr" rid="article-929.r6">[6]</xref>&#x000a0;Treatment doses were initially 30&#x02009;&#x000b5;g/kg/dose, followed by a repeat dose at 3 hours, then every 6 hours, and there is a hypothesis that this helped reduce the storage of catecholamines.<xref ref-type="bibr" rid="article-929.r7">[7]</xref></p>
      </sec>
      <sec id="article-929.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Prazosin is an alpha-1 adrenergic receptor antagonist. Alpha-1-receptors are present on smooth muscle, as in the blood vessel walls, the prostate, urethra, iris dilator muscle, and brain. Alpha 1 antagonists cause smooth muscle relaxation, which can, in turn, cause a decrease in blood pressure by decreasing systemic vascular resistance. This medication can also cross the blood-brain barrier.<xref ref-type="bibr" rid="article-929.r8">[8]</xref>&#x000a0;This mechanism allows for cognitive effects and hence its use in PTSD and PTSD-associated nightmares.&#x000a0;</p>
        <p>CYP450 enzymes hepatically metabolize this medication. The half-life is approximately 2.5 hours; however, it persists longer in chronic renal failure and congestive heart failure.<xref ref-type="bibr" rid="article-929.r9">[9]</xref>&#x000a0;No renal adjustments are necessary for chronic kidney disease or patients on hemodialysis or peritoneal dialysis. &#x000a0;</p>
      </sec>
      <sec id="article-929.s4" sec-type="Administration">
        <title>Administration</title>
        <p>The route for the administration of prazosin is oral. Doses of the medication include a 1 mg capsule, 2 mg capsule, and a 5 mg capsule.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypertension treatment doses (in adults)<xref ref-type="bibr" rid="article-929.r10">[10]</xref>:&#x000a0;2 to 20 mg divided into 2 to 3 times daily doses</p>
          </list-item>
          <list-item>
            <p>BPH treatment doses:&#x000a0;0.5 to 1 mg twice daily, up to 4 mg/day</p>
          </list-item>
          <list-item>
            <p>PTSD treatment doses <xref ref-type="bibr" rid="article-929.r11">[11]</xref>:&#x000a0;Initiate at 1mg. Maintenance at 2 to 6 mg nightly. Higher doses have seen use in military personnel, up to 16 mg nightly.</p>
          </list-item>
          <list-item>
            <p>Raynaud syndrome treatment doses:&#x000a0;1 mg three times daily</p>
          </list-item>
          <list-item>
            <p>Scorpion envenomation treatment doses:&#x000a0;30&#x02009;&#x000b5;g/kg/dose, followed by a repeat dose at 3 hours, then every 6 hours</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-929.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Serious Adverse Effects</bold>
</p>
        <p>Serious adverse effects include first-dose hypotension, and therefore it is recommended to take the initial dose at night. Also, patients may develop orthostatic hypotension and syncope. In cataract surgeries, patients taking prazosin may develop intraoperative floppy iris syndrome (IFIS) due to the drug's effect on the alpha receptors on the iris dilator muscle. However, some patients develop IFIS without using alpha-adrenergic receptor antagonists prior to surgery <xref ref-type="bibr" rid="article-929.r12">[12]</xref>.&#x000a0; Other serious adverse effects include priapism.&#x000a0;</p>
        <p>Common side effects found in 5&#x000a0;to 10% of patients are dizziness, headaches, drowsiness, lack of energy, weakness, palpitations, and nausea. An extensive list of side effects can be found below with their occurrence rates.&#x000a0;</p>
        <p>
<bold>Serious Adverse Effects</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>First dose hypotension</p>
          </list-item>
          <list-item>
            <p>Orthostatic hypotension</p>
          </list-item>
          <list-item>
            <p>Intraoperative Floppy iris syndrome</p>
          </list-item>
          <list-item>
            <p>Priapism</p>
          </list-item>
          <list-item>
            <p>Syncope</p>
          </list-item>
        </list>
        <p>
<bold>Common Adverse Effects (5&#x000a0;to 10% of patients) (Koola)</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Dizziness</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Drowsiness</p>
          </list-item>
          <list-item>
            <p>Lack of energy</p>
          </list-item>
          <list-item>
            <p>Weakness</p>
          </list-item>
          <list-item>
            <p>Palpitations</p>
          </list-item>
          <list-item>
            <p>Nausea&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Less Common Adverse Effects (1&#x000a0;to 4%)</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Vomiting</p>
          </list-item>
          <list-item>
            <p>Diarrhea</p>
          </list-item>
          <list-item>
            <p>Constipation</p>
          </list-item>
          <list-item>
            <p>Edema</p>
          </list-item>
          <list-item>
            <p>Orthostatic hypotension</p>
          </list-item>
          <list-item>
            <p>Dyspnea&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Syncope</p>
          </list-item>
          <list-item>
            <p>Vertigo&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Depression</p>
          </list-item>
          <list-item>
            <p>Rash</p>
          </list-item>
          <list-item>
            <p>Urinary frequency</p>
          </list-item>
          <list-item>
            <p>Nasal congestion</p>
          </list-item>
          <list-item>
            <p>Vertigo&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Nervousness</p>
          </list-item>
        </list>
        <p>
<bold>Rare Adverse Effects (&#x0003c;1%)</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Abdominal pain</p>
          </list-item>
          <list-item>
            <p>Tachycardia</p>
          </list-item>
          <list-item>
            <p>Paresthesias</p>
          </list-item>
          <list-item>
            <p>Hallucinations</p>
          </list-item>
          <list-item>
            <p>Pruritus&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Incontinence&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Impotence and priapism</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-929.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Previous anaphylaxis with prazosin is an absolute contraindication. Otherwise, there are no absolute contraindications of this medication, and there are no black box warnings. As with all medications, the clinician should avoid prescribing prazosin if there is a hypersensitivity or prior adverse effect with other medications in this class (including terazosin, tamsulosin, doxazosin). Caution should be used in patients with hypotension due to the potential adverse effect of orthostatic hypotension, especially considering the first-dose phenomenon associated with the initiation of therapy with prazosin.&#x000a0;Caution is also advisable in the setting of cataracts as antagonism of the alpha-1 receptors on the iris dilator muscle can contribute to floppy iris syndrome.&#x000a0;</p>
        <p>This medication is a Category C medication in pregnancy, suggesting insufficient data to support its use in humans. Other antihypertensive&#x000a0;drugs with better safety profiles should be used first in pregnancy.</p>
      </sec>
      <sec id="article-929.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The use of prazosin in the setting of other vasodilatory medication or other antihypertensives increases the propensity for orthostatic hypotension. This medication does not require routine drug monitoring. However, if patients present with any severe side effects, including syncope, weakness, tachycardia, impotence, orthostatic hypotension, or others, as listed above, the provider should consider alternative treatment options.&#x000a0;</p>
      </sec>
      <sec id="article-929.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There is no direct toxicity with this medication. High doses and overdoses could lead to hypotension, and patients should be supported clinically with volume resuscitation if necessary or pressor support.&#x000a0;</p>
        <p>The literature reports&#x000a0;a case of an overdose of prazosin in a pediatric patient with hypotension, which was refractory to volume resuscitation, epinephrine, and norepinephrine support. This patient had concomitant ingestion with naproxen and acetaminophen. Given the hepatic metabolism of both acetaminophen and prazosin, this likely led to the prolonged clearing of the medication. The patient did respond to vasopressin.<xref ref-type="bibr" rid="article-929.r13">[13]</xref></p>
      </sec>
      <sec id="article-929.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>WHile prazosin is a well-tolerated medication and safe when used as indicated, it nonetheless requires the effort of an interprofessional team to manage and monitor care properly. This starts with the prescriber (MD, DO, NP, or PA), who should only use the drug when indicated. Nursing staff can answer patient questions and provide initial counsel on how to take the medication and how to watch for potential adverse reactions. The pharmacist can provide additional counseling on dosing and administration while also checking for drug-drug interacitons. These interprofessional measures will enhance patient outcomes while minimizing adverse events. [Level 5]</p>
        <p>Evidence-based literature is reviewed in this article to help support the use of prazosin. This literature includes the articles noted in references. Patients should review the package insert and be cognizant of the potential side effects and report any new potential adverse effects to their healthcare provider.&#x000a0;</p>
      </sec>
      <sec id="article-929.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=929&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=929">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/929/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=929">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-929.s11">
        <title>References</title>
        <ref id="article-929.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>James</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Oparil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Cushman</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Dennison-Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Handler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lackland</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>LeFevre</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>MacKenzie</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Ogedegbe</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Svetkey</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Townsend</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Narva</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Ortiz</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).</article-title>
            <source>JAMA</source>
            <year>2014</year>
            <month>Feb</month>
            <day>05</day>
            <volume>311</volume>
            <issue>5</issue>
            <fpage>507</fpage>
            <page-range>507-20</page-range>
            <pub-id pub-id-type="pmid">24352797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-929.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lepor</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Alpha blockers for the treatment of benign prostatic hyperplasia.</article-title>
            <source>Rev Urol</source>
            <year>2007</year>
            <season>Fall</season>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>181</fpage>
            <page-range>181-90</page-range>
            <pub-id pub-id-type="pmid">18231614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-929.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kung</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Espinel</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Lapid</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>Treatment of nightmares with prazosin: a systematic review.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>87</volume>
            <issue>9</issue>
            <fpage>890</fpage>
            <page-range>890-900</page-range>
            <pub-id pub-id-type="pmid">22883741</pub-id>
          </element-citation>
        </ref>
        <ref id="article-929.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wollersheim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Thien</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fennis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>van Elteren</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>van 't Laar</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>1986</year>
            <month>Aug</month>
            <volume>40</volume>
            <issue>2</issue>
            <fpage>219</fpage>
            <page-range>219-25</page-range>
            <pub-id pub-id-type="pmid">3731684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-929.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bholah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bunchman</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>Review of Pediatric Pheochromocytoma and Paraganglioma.</article-title>
            <source>Front Pediatr</source>
            <year>2017</year>
            <volume>5</volume>
            <fpage>155</fpage>
            <pub-id pub-id-type="pmid">28752085</pub-id>
          </element-citation>
        </ref>
        <ref id="article-929.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodrigo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gnanathasan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Management of scorpion envenoming: a systematic review and meta-analysis of controlled clinical trials.</article-title>
            <source>Syst Rev</source>
            <year>2017</year>
            <month>Apr</month>
            <day>08</day>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>74</fpage>
            <pub-id pub-id-type="pmid">28390429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-929.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Prazosin: a pharmacological antidote for scorpion envenomation.</article-title>
            <source>J Trop Pediatr</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>52</volume>
            <issue>2</issue>
            <fpage>150</fpage>
            <page-range>150-1</page-range>
            <pub-id pub-id-type="pmid">16537569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-929.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gopalakrishna</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Popoola</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nemetalla</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Two Case Reports on Use of Prazosin for Drug Dreams.</article-title>
            <source>J Addict Med</source>
            <year>2016</year>
            <season>Mar-Apr</season>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>131</fpage>
            <page-range>131-3</page-range>
            <pub-id pub-id-type="pmid">26900667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-929.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jaillon</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of prazosin.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1980</year>
            <season>Jul-Aug</season>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>365</fpage>
            <page-range>365-76</page-range>
            <pub-id pub-id-type="pmid">6994981</pub-id>
          </element-citation>
        </ref>
        <ref id="article-929.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>e13</fpage>
            <page-range>e13-e115</page-range>
            <pub-id pub-id-type="pmid">29133356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-929.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Prazosin in the treatment of PTSD.</article-title>
            <source>J Psychiatr Pract</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>253</fpage>
            <page-range>253-9</page-range>
            <pub-id pub-id-type="pmid">25036580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-929.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zaman</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bach</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Junaid</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Papatsoris</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Pati</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Masood</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Buchholz</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>The floppy iris syndrome - what urologists and ophthalmologists need to know.</article-title>
            <source>Curr Urol</source>
            <year>2012</year>
            <month>May</month>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-7</page-range>
            <pub-id pub-id-type="pmid">24917702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-929.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Refractory Hypotension Caused by Prazosin Overdose Combined With Acetaminophen and Naproxen Toxicity: A Case Report and Review&#x000a0;of the Literature.</article-title>
            <source>J Emerg Med</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>55</volume>
            <issue>6</issue>
            <fpage>e141</fpage>
            <page-range>e141-e145</page-range>
            <pub-id pub-id-type="pmid">30287134</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
